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experienced graft failure within three months and a third
one within 14 months post transplant (two of whom
underwent successful second transplants 12 mos and
18 mos later while the third elected to not undergo
retransplantation and is now transfusion dependent). 6
patients became durably engrafted and remain disease-free.
Since 3 of the 9 patients rejected their grafts, the
conditioning regimen was modiﬁed to include the same
three agents but with alemtuzumab given between days -21
and -19. Results in ﬁve subsequent pts have yielded no
instances of graft rejection. Due to its relatively long half-life
(15-21 days), alemtuzumab, when given close to the day of
stemcell infusion,mayreduce the likelihoodof acuteGvHDbut
may also lead to in-vivo T-cell depletion of the donor graft,
thereby increasing the probability of graft loss. In this small
study, this latter effect outweighed the possible beneﬁt of
reducing the likelihoodof acuteGvHD.Thismaybeparticularly
true in this patient populationwhich comes to transplantation
with an intact, and often sensitized, immune system.303
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Background: Rare diseases requiring hematopoietic stem
cell transplantation present a challenge for pediatric BMT
centers. The patients present at a low frequency, and there
are often no established conditioning regimens for these
disorders. We report the conditioning regimen, donor
source, and outcomes for the following rare disorders
transplanted at our program from January 2011 through
January 2014. During the past three years we have had pa-
tients present with the following: Fanconi anemia (FA),
Hemophagocytic Lymphohistiocytosis (HLH), Congenital
Amegakaryocytic Thrombocytopenia (CAMT), Chediak-
Higashi Syndrome (CHS), Langerhans Cell Histiocytosis
(LCH), Beta-thalassemia, Juvenile Myelomonocytic Leukemia
(JMML), Immunodeﬁciency Syndrome with Myelodysplastic
Syndrome (IDS/MDS), and Cartilage Hair Hypoplasia (CHH).
Methods: We are the sole pediatric HSCT center in our state.
We treat patients with rare disorders that require HSCT at
our center, and are reporting the management strategy and
outcomes for this wide variety of rare disorders.Table 1
Patient characteristics and outcomes for patients with rare disorders.
Patient Disease Donor / HLA Match Conditioning
1 HLH UCB- 5/6 Bu/VP/CY/ATG
2 HLH MSD BM- 10/10 Alem/Flu/Mel
3 FA BM- 10/10 TBI/Flu/CY/ATG
4 B-thal MRD BM- 8/10 Bu/CY/ATG
5 IDS/MDS BM- 9/10 Bu/CY/ATG
6 LCH MSD BM- 10/10 Alem/Flu/Mel
7 CHH MSD UCB- 6/6 Bu/CY/ATG
8 JMML MSD BM- 10/10 Bu/CY/Mel
9 CAMT BM- 10/10 CY/ATG/TBI
10 HLH BM- 9/10 Alem/Flu/Mel
11 CHS BM- 10/10 Bu/CYResults: The patients were referred to or diagnosed at our
institution from January 2011 to January 2014. All patients
were transplanted with the best available donor using bone
marrow (BM) or umbilical cord blood (UCB). Conditioning
regimens and treatment plans were determined by the BMT
attending team based on reviews of the literature and varied
with type of disease. The BMT coordinators and nurse prac-
titioners were educated about the disorders and then
educated the inpatient and outpatient teams. The PharmD
created order sets for patients based on the treatment plans.
Patient characteristics and outcomes are presented in Table 1.
The day 100 survival was 100%. Nine of 11 patients are alive
and well (A/W) with no evidence of disease.
Conclusions: Our program has treated a variety of rare disor-
ders with a > 80% Event-Free-Survival. Our data suggests that
excellent outcomes can be obtained at small-moderate sized
BMT programs when the team approach is used to create the
best-practices plan of care for each individual patient.304
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Background: TMA with high-risk features at diagnosis,
including terminal complement activation measured by
elevated sC5b-9 and proteinuria, is associated with very
high mortality as <20% of such untreated patients survive
at 1 year after HSCT (Jodele et al, Blood 2014). In a thera-
peutic pilot study, we observed TMA resolution in 4 of
6 patients with high-risk TMA who achieved complement
blockade using eculizumab, with dosing guided pharma-
codynamically by measurement of total hemolytic
complement activity (CH50) (Jodele et al, BBMT 2014). We
now present an expanded patient cohort treated with
eculizumab.ANC > 500 (Day) Platelet > 20K (Day) Outcome
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Figure. Overall survival in HSCT patients with high risk TMA
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a dosing schedule adjusted to maintain a suppressed CH50
which correlated with a therapeutic eculizumab level of
>99mg/mL. Response was deﬁned as resolution of hemato-
logic TMA parameters, normalization of sC5b-9, and a 50%
increase in the cystatin C-estimated glomerular ﬁltration
rate (CystC GFR). Data were compared to historical controls
from our prospective observational study with the same
high-risk TMA features who did not receive eculizumab
(n¼11). In both cohorts, high-risk TMA was diagnosed pro-
spectively using uniform clinical and laboratory criteria.
Results: 12 of 18 (67%) patients treated with eculizumab
achieved resolution of TMA. Median number of eculizumab
doses given for therapy were 16 (range 4-38). All patients
required frequent drug dosing 2-3 times per week for at
least the ﬁrst 2 weeks to achieve and maintain therapeutic
eculizumab levels. Patients with sC5b-9 levels >488ng/mL
at diagnosis (normal <244ng/mL) required 11-13 days of
therapy to normalize sC5b-9 and to achieve terminal com-
plement blockade before clinical response could be
observed, while patients with sC5b-9 level 488 required
2-5 days to block complement. All responders were able to
discontinue therapy without TMA relapse with median
follow up time of 37 weeks (range 8-128 weeks). One
responder died from GVHD three months after resolution ofPrimary Disease Transplant Resistance Weeks of elevated
ALL AlloUPSCT N 9
CML Allo UBMT N 4, 20
AML Allo UBMT UL54 site T5031 20
AML AlloUPSCT N 3
ALL AlloUPSCT UL97 site A594V 30
HLH Allo RBMT NA 7TMA. Six patients (33%) who did not respond to therapy
died with active TMA after receiving median of 4 doses
(range 2-24) of eculizumab. We did not observe any in-
fections or toxicities attributed to eculizumab. Overall sur-
vival was signiﬁcantly better in the group treated with
eculizumab as compared to untreated historical controls
with high risk TMA (p¼0.002, Figure).
Conclusions: Terminal complement blockade by eculizumab
improves survival in patients with high risk TMA who
otherwise have a very poor outcome. Pharmacodynamic
monitoring is needed to optimize drug dosing to achieve
prompt complement blockade and clinical response. Therapy
can be safely discontinued after TMA is controlled.
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Background: Drug resistant cytomegalovirus (CMV)
has been described in pediatric hematopoietic stem cell
(HSCT) patients; however, clinical signiﬁcance is poorly
described.
Methods: With IRB approval we performed a retrospective
analysis of HSCT recipients with CMV reactivation between
January 2009 and February 2014. Per institution guidelines,
peripheral blood was screened twice weekly after transplant
via CMV polymerase chain reaction (PCR). Patients with
reactivation (>200 copies/ml) received pre-emptive therapy
with ganciclovir. Patients with neutropenia (ANC< 500/mcl)
received foscarnet. Indications for CMV drug resistance gene
testing included reactivation lasting beyond 2 weeks of
therapy, 10-fold rise in PCR or development of CMV disease.
Viracor IBT Laboratories performed PCR gene-sequencing
analysis for mutations of the UL97phototransferase and UL54
DNA polymerase genes.
Results: Of 34 patients with CMV reactivation, 5.8% (n¼2)
had drug resistant virus. One patient received only foscarnet
and had ganciclovir resistant virus. This patient had both
signiﬁcantly elevated and prolonged positive viral load. The
second patient was exposed to foscarnet, ganciclovir and
cidofovir prior to resistance testing and had virus resistant to
ganciclovir and cidofovir.
We hypothesize patients with CMV disease are at risk of
having drug resistant virus if they also have >20-fold rise in
viral copies and/or prolonged viremia. Five patients had
>20 fold increase in viral copies after starting anti-viral
therapy, one of which had ganciclovir resistant virus. The
second patient with drug resistant virus had only a 5-fold
rise in viral copies but failed to respond to anti-viral therapy
with persistent viremia 30 weeks from the start of anti-viralPCR Fold PCR increase Anti-Viral Therapies Disease
54 Fos/Gan/Val N
19, 64 Gan N
69 Fos/Gan/Cid Colitis
23 Fos N
5 Fos/Val Pneumonitis
295 Fos N
